BL-M11D1

DRUG4 trials

Sponsors

Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc.

Conditions

Acute Myeloid LeukemiaMyelodysplastic SyndromesRelapsed/Refractory Acute Myeloid LeukemiaRelapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Phase 1

A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

RecruitingNCT05924750

Sichuan Baili Pharmaceutical Co., Ltd.Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Start: 2023-08-02End: 2027-12-31Target: 130Updated: 2025-09-26

Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1

RecruitingNCT06714591

SystImmune Inc.Relapsed/Refractory Acute Myeloid Leukemia

Start: 2024-12-19End: 2027-03-30Target: 120Updated: 2026-07-21

A Study of BL-M11D1 in Patients With Relapsed/Refractory Myelodysplastic Syndromes

Not yet recruitingNCT07591168

Sichuan Baili Pharmaceutical Co., Ltd.Myelodysplastic Syndromes

Start: 2026-09-01End: 2028-12-01Target: 92Updated: 2026-08-27

Phase 2

A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia

RecruitingNCT07255872

Sichuan Baili Pharmaceutical Co., Ltd.Acute Myeloid Leukemia

Start: 2026-04-02End: 2027-12-01Target: 216Updated: 2026-09-10